Page 4 - Pharmascience Inc News Today

September 21, 2022, marked the fifth anniversary of the significant amendments to the Patented Medicines (Notice of Compliance) Regulations (Regulations). This article provides an...

On August 23, 2022, the Federal Court issued its public judgment and reasons in two actions under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (the...

On August 4, 2022, the Federal Court of Appeal (FCA) dismissed Pharmascience’s appeal of a Federal Court decision upholding the validity of Canadian Patent Nos. 2,461,202 (the 202...

Making, constructing, using, selling generic version would infringe patent's claims

The Federal Court of Appeal (FCA) dismissed an appeal by Biogen and a cross-appeal by Taro from a decision of the Federal Court... dismissing two actions by Biogen under the Patented...

Lupin on Monday said it has received a tentative approval from the US health regulator to market Dasatinib tablets, used to treat certain types of cancer, in America.

Dasatinib Tablets (RLD Sprycel) has expected annual sales in the United States of USD 1,569 million, as per the IQVIA MAT June 2022.

A pain medication is subject to a recall in Canada because of a packaging error. The problem is that bottles from a lot of 2-milligram pms-Hydromorphone tablets from the company Pharmascience Inc. may include some stronger 8-milligram tablets.

Historically, claim fees have not been payable at any time during the pendency of a Canadian patent application or term of the patent. This will change soon, and the present article...

Pharmascience International is proud to enter the United States market with the launch of Bortezomib 3.5 mg/vial - read this article along with other careers information, tips and advice on BioSpace